Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma”

83 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 83 results

Early research (Phase 1)UnknownNCT04984434
What this trial is testing

Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD 68
Testing effectiveness (Phase 2)UnknownNCT00800059
What this trial is testing

Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma

Who this might be right for
Multiple Myeloma
Ottawa Hospital Research Institute 27
Early research (Phase 1)Study completedNCT01118689
What this trial is testing

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple MyelomaWaldenstrom Macroglobulinemia
Millennium Pharmaceuticals, Inc. 39
Testing effectiveness (Phase 2)UnknownNCT01435720
What this trial is testing

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMantle Cell Lymphoma in Relapse+3 more
Senesco Technologies, Inc. 15
Early research (Phase 1)Study completedNCT02278315
What this trial is testing

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Cellectar Biosciences, Inc. 31
Early research (Phase 1)Ended earlyNCT03755154
What this trial is testing

Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Who this might be right for
Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Non-Hodgkin LymphomaRelapsed or Refractory Multiple Myeloma+1 more
Institut de Recherches Internationales Servier 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04586426
What this trial is testing

The Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 228
Testing effectiveness (Phase 2)Active Not RecruitingNCT03715478
What this trial is testing

Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Canadian Myeloma Research Group 120
Early research (Phase 1)Ended earlyNCT05027594
What this trial is testing

Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Nerviano Medical Sciences 5
Early research (Phase 1)Study completedNCT01568294
What this trial is testing

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 12
Early research (Phase 1)WithdrawnNCT05918250
What this trial is testing

MRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.
Early research (Phase 1)Study completedNCT01344876
What this trial is testing

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaAcute Myeloid Leukemia+2 more
Otsuka Pharmaceutical Co., Ltd. 20
Early research (Phase 1)Study completedNCT01689987
What this trial is testing

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
OHSU Knight Cancer Institute 18
Testing effectiveness (Phase 2)Ended earlyNCT04735575
What this trial is testing

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Shanghai EpimAb Biotherapeutics Co., Ltd. 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04557098
What this trial is testing

Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 194
Early research (Phase 1)Study completedNCT01457417
What this trial is testing

DKN-01 in Multiple Myeloma or Advanced Solid Tumors

Who this might be right for
Multiple MyelomaSolid TumorsNon-Small Cell Lung Cancer
Leap Therapeutics, Inc. 32
Early research (Phase 1)Looking for participantsNCT05652335
What this trial is testing

JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Who this might be right for
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC 180
Early research (Phase 1)Active Not RecruitingNCT06604715
What this trial is testing

JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC 17
Early research (Phase 1)Active Not RecruitingNCT01562405
What this trial is testing

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Massachusetts General Hospital 33
Early research (Phase 1)Active Not RecruitingNCT03145181
What this trial is testing

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 302
Next Page